U.S., July 1 -- ClinicalTrials.gov registry received information related to the study (NCT07044336) titled 'Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)' on June 23.
Brief Summary: This is a Phase III, 2-arm, randomized, open label, multicenter, global study assessing the efficacy and safety of puxitatug samrotecan compared to physician's choice of chemotherapy (doxorubicin or paclitaxel) in participants with B7-H4 selected advanced/metastatic EC that progressed following platinum based chemotherapy and anti-PD-1/anti-PD-L1 therapy.
Study Start Date: July 16
Study Type: INTERVENTIONAL
Condition:
Endometrial Cancer
Malignant Solid Tumour
Intervention:
DRUG: Pu...